Publications by authors named "Sergei Astakhov"
Article Synopsis
- * Conducted as a double-masked, randomized phase 3 trial, participants were assigned to receive either SB15 or AFL, with some switching treatments mid-study, allowing for a direct comparison of outcomes.
- * Results showed that both SB15 and AFL had similar impacts on visual acuity and retinal thickness, and both safety and immunogenicity profiles were comparable, indicating that SB15 could be a viable alternative to AFL in nAMD treatment.
Article Synopsis
- Aflibercept biosimilars like SB15 can enhance treatment options for retinal diseases, potentially increasing patient access to effective therapies.
- A phase 3 trial was conducted with 449 participants aged 50 and older with neovascular age-related macular degeneration to compare the efficacy and safety of SB15 and the reference drug, Aflibercept (AFL).
- The results showed that SB15 produced comparable improvements in visual acuity as AFL after 8 weeks, indicating equivalence in efficacy between the two treatments.
Glaucoma is a progressive optic neuropathy associated with damage to retinal ganglion cells (RGCs) and disrupted circadian rhythms. Melatonin is a promising substance to ameliorate glaucoma-associated compromised circadian rhythms, sleep, mood, and retinal cells function. However, studies estimating melatonin effects in glaucoma are currently lacking.
View Article and Find Full Text PDFArticle Synopsis
- Exfoliation syndrome is a systemic disorder characterized by the buildup of abnormal protein aggregates in the eye, leading to increased risk of glaucoma and potential blindness.
- The study aimed to explore the association between exfoliation syndrome and rare genetic variants that could affect protein function, using whole-exome sequencing on participants from 14 countries over 20 years.
- Results showed that individuals with exfoliation syndrome were more likely to have harmful genetic variants in the CYP39A1 gene compared to those without the condition, indicating a potential genetic factor in the disorder.
Parameters of 24-h rhythm in intraocular pressure (IOP) were assessed in patients with stable or advanced primary open-angle glaucoma (S-POAG/A-POAG) and referenced to the phase of "marker" circadian temperature rhythm of each patient. Body temperature and IOP were measured over a 72-h span in 115 participants (65 S-POAG and 50 A-POAG). Retinal Ganglion Cell (RGC) damage was assessed by high-definition optical coherence tomography.
View Article and Find Full Text PDFPurpose:: We compared the efficacy and safety of ranibizumab versus ranibizumab plus scatter laser photocoagulation (SLP) in patients with chronic post-central retinal vein occlusion (CRVO) macular edema (ME).
Methods:: This prospective non-randomized pilot study included 250 patients with peripheral retinal ischemia and CRVO-related ME. The mean follow-up period was 24.
Article Synopsis
- Exfoliation syndrome (XFS) is a significant risk factor for secondary glaucoma, contributing to blindness globally, with known genetic variants in LOXL1 and CACNA1A linked to the condition.
- Researchers conducted a study analyzing samples from multiple countries, discovering a rare protective allele at LOXL1 and refining its association, which had been previously inconsistent across different populations.
- A genome-wide association study identified seven significant genetic loci related to XFS, providing new insights into its biological mechanisms and emphasizing the role of rare LOXL1 variants in the disease's development.
Article Synopsis
- Exfoliation syndrome (XFS) is a common cause of a type of eye disease called open-angle glaucoma.
- Researchers studied the DNA of nearly 1,500 people with XFS and compared it to over 1,100 healthy people from Japan, and then looked at even more data from around the world.
- They found a new gene that seems to increase the chances of getting XFS and confirmed another gene that behaves differently in people from different backgrounds.
Laser-assisted in situ keratomileusis (LASIK) is commonly used to correct refractive defects. The procedure frequently results in dry eye symptoms, usually of short but sometimes longer duration. This study was designed to assess dry eye and ocular tolerability after LASIK in patients treated with a preservative-free lacrimal substitute (Hylabak®) or preserved lacrimal substitute (Systane®).
View Article and Find Full Text PDF